Iron Therapy

Iron deficiency remains the most prevalent nutritional disorder worldwide, affecting an estimated two billion people and representing the single most common cause of anemia across all age groups. The recognition that iron is integral to blood formation stretches back millennia, yet the pharmacological refinement of iron therapy — both oral and parenteral — is a remarkably modern achievement. Early physicians observed that patients with pallor and weakness improved when given iron-containing tonics, but the biochemical rationale for these observations awaited advances in hematology, inorganic chemistry, and drug formulation. Understanding this historical trajectory illuminates why contemporary clinicians now have access to a sophisticated armamentarium of iron preparations, each engineered to optimize bioavailability, minimize toxicity, and match specific clinical scenarios.

The central question that iron therapy addresses is straightforward yet clinically nuanced: how do we safely and efficiently replenish body iron stores in patients whose supply is inadequate for the demands of erythropoiesis and cellular metabolism? Answering this question requires understanding iron absorption physiology, the pharmacokinetics of different formulations, adverse-effect profiles, and evidence-based indications — topics explored in the sections that follow.

Before exploring specific preparations, clinicians must internalize several foundational principles that govern how iron behaves in the body and how pharmacologic intervention interacts with physiologic regulation. The body tightly controls total iron content (approximately 3–4 g in adults), primarily through modulation of intestinal absorption, because there is no regulated excretory mechanism for iron. This single fact underpins both the therapeutic rationale for supplementation and the toxicologic dangers of iron overload.

The diagram above highlights the two pharmacologically distinct routes of iron repletion. Oral iron enters the duodenal enterocyte as Fe²⁺ via the divalent metal transporter 1 (DMT-1). It is then exported basolaterally through ferroportin — the only known cellular iron export channel — into the plasma, where it is oxidized back to Fe³⁺ and loaded onto transferrin. The hepcidin–ferroportin axis serves as a critical checkpoint: when hepcidin rises (in states of iron sufficiency or systemic inflammation), ferroportin is internalized and degraded, effectively shutting down iron export and limiting the efficacy of oral supplementation. This mechanism explains why oral iron often fails in the anemia of chronic disease, where inflammatory cytokines, especially IL-6, drive hepcidin overexpression.

Parenteral iron formulations circumvent the gut entirely. After intravenous infusion, iron–carbohydrate complexes are phagocytosed by reticuloendothelial macrophages in the liver and spleen, which then process the complex, release iron intracellularly, and export it via ferroportin into transferrin. The rate of iron release from the carbohydrate shell varies by formulation and determines both the safety profile (slower release reduces labile free-iron peaks) and the permissible infusion speed. Importantly, even IV iron ultimately depends on ferroportin for macrophage export, meaning that severely elevated hepcidin can delay — though not prevent — iron mobilization from the reticuloendothelial system.

The dosing of iron therapy is guided by quantitative estimation of the total body iron deficit. For oral iron, this translates to selecting a preparation with an adequate elemental iron content and prescribing it for a duration sufficient to replenish both the hemoglobin compartment and depleted stores. For parenteral iron, the Ganzoni equation remains the most widely referenced formula for calculating the total replacement dose, although many clinicians now use simplified weight-based protocols endorsed by recent guidelines.

The choice between oral and parenteral iron hinges on severity of deficiency, tolerability, underlying etiology, and clinical urgency. Oral preparations are first-line for most ambulatory patients with mild-to-moderate iron deficiency anemia because of their low cost, ease of administration, and acceptable efficacy. Parenteral formulations are reserved for patients with malabsorption (e.g., celiac disease, post-bariatric surgery), intolerance of oral iron, chronic kidney disease requiring erythropoiesis-stimulating agents, inflammatory bowel disease with active inflammation, or need for rapid repletion (e.g., perioperative setting or late pregnancy).

Consider a 60 kg woman with iron deficiency anemia and a current hemoglobin of 8.5 g/dL. She has failed a 6-week trial of oral ferrous sulfate due to intractable nausea and constipation. Her gastroenterologist decides to administer intravenous ferric carboxymaltose and asks you to calculate the total iron deficit using the Ganzoni equation, then determine the number of infusion sessions required.

All iron preparations carry the potential for adverse effects, though the profile differs substantially between oral and parenteral routes. Appreciating these differences allows clinicians to counsel patients proactively, improve adherence, and choose appropriate formulations for individual clinical scenarios. Moreover, iron participates in numerous drug interactions — some pharmacokinetic, others pharmacodynamic — that can compromise the efficacy of co-administered medications or of the iron itself.

As understanding of iron biology matures, iron therapy is evolving beyond simple repletion of a nutritional deficit. Several clinical contexts demand nuanced approaches that extend foundational principles into complex pathophysiology. The table below contrasts standard iron deficiency anemia management with advanced clinical scenarios that healthcare students are increasingly expected to understand.

The concept of functional iron deficiency is particularly important in nephrology and cardiology. In chronic kidney disease, reduced erythropoietin production and chronic inflammation combine to create an environment where iron is sequestered in macrophages rather than mobilized to the marrow. KDIGO guidelines recommend maintaining TSAT > 20% and ferritin > 100 ng/mL (or > 200 ng/mL in dialysis patients) before and during ESA therapy. The HIF-prolyl hydroxylase inhibitors represent a paradigm shift: by stabilizing hypoxia-inducible factor, drugs like roxadustat and daprodustat stimulate endogenous erythropoietin production while concurrently suppressing hepcidin, potentially enhancing oral iron absorption — an elegant pharmacologic convergence that may reduce the need for both injectable ESAs and IV iron.